Cargando…
Omani experience with the use of factor IX Fc fusion protein
We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophyla...
Autores principales: | Alzadjali, Shireen I, Wali, Yasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296795/ https://www.ncbi.nlm.nih.gov/pubmed/34290003 http://dx.doi.org/10.1136/bcr-2020-241154 |
Ejemplares similares
-
COVID-19 in Omani Children with Hemato-Oncology Diseases
por: Al Yazidi, Laila S, et al.
Publicado: (2020) -
Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023) -
Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
por: McCue, J, et al.
Publicado: (2014) -
Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016) -
Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)